In recent months, the FDA has approved three sublingual oral immunotherapy tablets for treating grass and ragweed allergies, as well as omalizumab for chronic idiopathic urticaria.

An FDA advisory panel advised against a proposal to allow montelukast sodium as an over-the-counter treatment for patients with allergic rhinitis and other respiratory allergies. Here are highlights from Healio Allergy/Immunology:

  • FDA approves Oralair, first SLIT agent for grass allergies
  • Grastek, second SLIT agent for grass allergies, approved
  • Ragwitek, first SLIT agent for ragweed allergies, approved
  • FDA approves Xolair for chronic idiopathic urticaria
  • FDA advisory panel advises against Singulair OTC